Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
about
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisBiologics registers in RA: methodological aspects, current role and future applications.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.Ten years with biologics: to whom do data on effectiveness and safety apply?Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.Evaluation of the RABBIT Risk Score for serious infectionsValidity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesTNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisValidation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm County.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaThe comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsRisk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.[How do register data support clinical decision-making?].Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analysesAssociation between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.APLAR rheumatoid arthritis treatment recommendations.Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisPhysicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA sAdalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Tumor necrosis factor inhibitors and infection complications.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
P2860
Q26852235-43F5E2E5-F646-449D-9092-A7D66EB94808Q30234303-7914DCFA-0904-46FB-830F-27C06809CC2CQ30717002-A35699F6-49C0-4E7D-B395-5EF9279F20AEQ30940329-B6514AF9-2359-4AAD-B0C4-8CB123193C11Q31151183-30E4DB31-BD1F-4610-8A37-F8100CEF0588Q33424116-8F7FF020-369A-4B9C-9CA2-33A5FC783E8BQ33516150-52A6C67D-C8DF-46C0-892D-6B52DF802D94Q33749195-4AB54E65-F54E-4C2A-B6D4-ADC2AEA50C92Q33778719-1D72C8B6-0562-4828-A5BD-09BF50252560Q33819684-D82B8A0E-F78B-493E-80C3-C25179C6BEDEQ34027648-52D5123F-B754-4309-B04B-7E610282E23FQ34065002-ED178B2F-7BA6-4584-AB8E-73FCEE8F1E8EQ34092564-F9C65A06-51F9-4AAB-85E7-B260F12A7B66Q34195402-5E7ED341-E4D2-46E4-8C52-8026E93AC674Q34216770-188AEAC8-6068-4F33-ABD8-668EA3DD8A8BQ34792330-E8627F95-300D-485A-B84D-0025DE65E999Q34996377-010C26F6-0549-4353-BC61-A602075FC334Q35018415-123560FF-89B0-4540-88D1-1FC60175612CQ35082559-91F19ECB-D113-4F62-9D97-0D561EFB006CQ35200349-07986A40-3869-4DC9-A03D-AC0AD0B35B47Q35237588-BC8FD9FB-F1DA-4B3C-BE46-D8E0A47FBD13Q35249608-AB76D681-806A-4F7C-8C12-C385A8DFFD4FQ35348182-08E0AEC9-395F-4330-A87B-049601F59EE4Q35585867-C4754794-02F3-403E-9A44-2FD21BD00B8BQ35617617-038097B2-A6C3-4F7A-97E4-2BE0A4C9B52AQ35617753-3EB3AE73-8A80-43A0-B36C-7C9DA8B18683Q35686918-B4748B55-CB09-481D-B36A-A3FE6D6CDB7EQ35705082-DB4EF0CC-BC14-42A3-A3D1-2B6D41C053C2Q35762912-A0AFA620-AB1E-48C1-AFEA-9238CE904AFDQ35899264-AEACAB32-40EB-4F50-AAE3-68BF3EDC4BC6Q36036975-6061F4C7-1D15-49B8-BA17-7CB8EF21836DQ36086443-E2C1BCC1-05AC-4978-B899-9AE9008FA1F1Q36150089-CE93236D-C173-44D2-B66C-30A23D014109Q36179586-3F6B1E18-D114-4582-B792-2B0CA6CDD946Q36220832-8D70202E-6962-45B8-BC2F-79F910B33C64Q36550842-CFD801B0-3583-465F-948C-19C409E0FE91Q36677345-5E072942-D5C4-484F-91AB-A72E8EFC8398Q36679750-E1682B06-B14B-489E-9F83-B15A5A32C52FQ36806922-1F26AECA-9E85-4F13-9EB0-87E41F98CAC2Q36942914-D4C637F4-A578-4C77-81E9-429AC01AAB9E
P2860
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Time-dependent increase in ris ...... treated with TNF antagonists.
@ast
Time-dependent increase in ris ...... treated with TNF antagonists.
@en
type
label
Time-dependent increase in ris ...... treated with TNF antagonists.
@ast
Time-dependent increase in ris ...... treated with TNF antagonists.
@en
prefLabel
Time-dependent increase in ris ...... treated with TNF antagonists.
@ast
Time-dependent increase in ris ...... treated with TNF antagonists.
@en
P2093
P2860
P50
P921
P356
P1476
Time-dependent increase in ris ...... treated with TNF antagonists.
@en
P2093
C Michael Fored
Eva Baecklund
Johan Askling
Jörgen Lysholm
Lars Cöster
Lena Brandt
Lennart Bertilsson
Lennart T Jacobsson
Nils Feltelius
Pierre Geborek
P2860
P304
P356
10.1136/ARD.2006.062760
P407
P577
2007-01-29T00:00:00Z